This article summarizes the most significant insider buying and selling activities for US stocks reported on Tuesday, December 17, 2024.
Top Insider Buys:
Pulse Biosciences (NASDAQ:PLSE): Robert Duggan, Chairman of the Board, made a substantial purchase of 1,000,000 shares of Pulse Biosciences. Following this acquisition, Duggan now directly owns 42,328,717 shares of the company. Additionally, he maintains indirect ownership through affiliated companies, holding 561,089 shares via Genius 24C Inc. and 400,877 shares through Blazon Corporation. This increased investment underscores Duggan's continued confidence in Pulse Biosciences, a company known for its innovative medical instruments and apparatus.
Centene Corp (NYSE:CNC): Christopher J. Coughlin, a director at Centene Corp, purchased 10,000 shares of the company's common stock at a weighted average price of $59.44 per share, totaling approximately $594,400. This insider purchase comes as the $29.19 billion healthcare provider trades near its 52-week low, with a modest P/E ratio of 9.98x. Following this transaction, Coughlin's total direct ownership increased to 36,357.926 shares, which includes 2,916 shares of restricted stock units subject to vesting requirements.
Expro Group Holdings N.V. (XPRO): Michael Jardon, the President and CEO of Expro Group Holdings N.V., acquired 45,200 shares of the company's common stock at an average price of $10.91 per share, totaling approximately $493,132. The acquisition comes as the stock trades near its 52-week low of $10.71, following a significant 48% decline over the past six months. Following this transaction, Jardon holds 336,674 shares directly, which includes a number of restricted stock units set to vest in the coming years.
Bicycle Therapeutics (NASDAQ:BCYC): Baker Bros. Advisors LP, along with its affiliates, including 667, L.P., and Baker Brothers Life Sciences LP, made significant purchases of Bicycle Therapeutics shares. These entities are known for their strategic investments in the life sciences sector. Julian and Felix Baker, who have significant influence over the investment activities of these funds, may indirectly benefit from these transactions due to their roles in the firm.
Inspirato Inc. (ISPO): Zamani Payam, Chief Executive Officer of Inspirato Inc., made significant acquisitions of the company's Class A common stock. On December 9, 2024, Payam acquired 728,863 shares at a price of $2,500,000 per share. Subsequently, on December 16, 2024, Payam acquired an additional 177,515 shares at a price of $600,000 per share. These transactions were part of an option exercise and a Guarantee Fee arrangement, respectively.
Top Insider Sells:
Olema Pharmaceuticals, Inc. (OLMA): Graham G. Walmsley, a director at Olema Pharmaceuticals, Inc., sold 700,761 shares at a price of $6.75 per share, amounting to a total transaction value of approximately $4.73 million. The shares were sold by Logos Opportunities Fund I LP and acquired by Logos Opportunities Fund IV LP, both of which are under the common control of Walmsley.
Hims & Hers Health, Inc. (HIMS): Andrew Dudum, the Chief Executive Officer of Hims & Hers Health, Inc., sold shares totaling approximately $6.24 million. The sales were executed at prices ranging from $28.78 to $32.63 per share. Prior to these sales, Dudum acquired 176,308 shares of Class A Common Stock through the exercise of stock options.
Veritone, Inc. (NASDAQ:VERI): Chad Steelberg, a director and significant stakeholder in Veritone, Inc., sold 504,657 shares of Veritone common stock at a price of $2.515 per share, amounting to a total transaction value of approximately $1.27 million. Following this transaction, Steelberg retains direct ownership of 31,861 shares and holds indirect stakes in various entities.
Tyler Technologies, Inc. (NYSE:TYL): H. Lynn Moore Jr., President and CEO of Tyler Technologies, Inc., sold 15,000 shares of the company's stock. The sale was executed through multiple transactions with prices ranging from $38.99 to $39.50 per share. In addition to the sale, Moore exercised options to acquire 6,752 shares of common stock at prices ranging from $402 to $432.12 per share.
Investors should stay tuned to insider buying and selling activities as they can provide valuable insights into a company's prospects. While insider transactions alone should not be the sole basis for investment decisions, they can offer clues about management's confidence in the company's future performance. However, it's important to consider these transactions in the context of broader market trends, company fundamentals, and individual investment goals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.